首页 › 基金 › Octagon Capital Advisors LP › PALI
Octagon Capital Advisors LP 对 PALI 的持仓历史
PALISADE BIO INC · 医疗保健
Octagon Capital Advisors LP 在 Q3 2026 的 13F 申报中披露持有 PALI(PALISADE BIO INC)10,276,317 股,市值约 US$13.9M,约占其申报组合的 1.85%,在其申报持仓中市值排名第 15 位。 Octagon Capital Advisors LP 最近 4 个申报季度中有 4 个季度披露了 PALI 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Octagon Capital Advisors LP 对 PALI 的持仓演变
Octagon Capital Advisors LP 于 Q4 2025 首次披露 PALI 持仓:9,567,898 股(约 US$22.5M)。 在 4 次申报中,Octagon Capital Advisors LP 1 次增持、0 次减持、2 次保持不变。 最近一期申报(Q3 2026)显示持股 10,276,317 股、市值约 US$13.9M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 9.57M | $22.48M | 新进 |
| Q1 2026 | 10.28M | $17.98M | 增持 |
| Q2 2026 | 10.28M | $21.48M | 持有 |
| Q3 2026 | 10.28M | $13.87M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 PALI 与 13F 数据
PALI(PALISADE BIO INC)属于医疗保健行业。我们追踪的基金中还有 75 只申报持有 PALI,申报仓位最大的包括:Soleus Capital Management, L.P. (US$20.2M), B Group, Inc. (US$15.4M), Boxer Capital Management, LLC (US$6.5M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 PALI 的基金
- Soleus Capital Management, L.P. 15.00M 股 · $20.24M · Q3 2026
- B Group, Inc. 11.41M 股 · $15.41M · Q3 2026
- Boxer Capital Management, LLC 4.80M 股 · $6.48M · Q3 2026
- Squadron Capital Management LLC 3.00M 股 · $4.05M · Q3 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 2.34M 股 · $3.15M · Q3 2026
- Propel Bio Management, LLC 2.22M 股 · $3.00M · Q3 2026
- PLATINUM INVESTMENT MANAGEMENT LTD 2.18M 股 · $2.95M · Q3 2026
- Creek Drive Management Group LLC 680.00K 股 · $918.00K · Q3 2026
- ACT CAPITAL MANAGEMENT, LLC 307.50K 股 · $642.67K · Q2 2026
- ACT Capital Partners, L.P. 307.50K 股 · $415.12K · Q3 2026
更多关于 Octagon Capital Advisors LP
常见问题
How long has Octagon Capital Advisors LP held PALI?
Octagon Capital Advisors LP has disclosed PALI holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Octagon Capital Advisors LP's current position in PALI?
As of Q3 2026, Octagon Capital Advisors LP holds 10.28M shares of PALI (PALISADE BIO INC), valued at $13.87M, representing 1.85% of its reported portfolio and ranking #15.
Has Octagon Capital Advisors LP been buying or selling PALI?
In the latest 13F filing (Q3 2026), Octagon Capital Advisors LP held unchanged its position in PALI.
Which other funds hold PALI?
Other major institutional holders of PALI include Soleus Capital Management, L.P., B Group, Inc., Boxer Capital Management, LLC, among 75 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.